Cargando…
Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke
Background: There is growing interest in the use of new biomarkers such as glycated albumin (GA), but data are limited in acute ischemic stroke. We explored the impact of GA on short-term functional outcomes as measured using the modified Rankin Scale (mRS) at 3 months compared to glycated hemoglobi...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000654/ https://www.ncbi.nlm.nih.gov/pubmed/33800924 http://dx.doi.org/10.3390/brainsci11030337 |
_version_ | 1783671047070941184 |
---|---|
author | Kim, Yerim Lee, Sang-Hwa Kang, Min Kyoung Kim, Tae Jung Jeong, Han-Yeong Lee, Eung-Joon Bae, Jeonghoon Jeon, Kipyoung Nam, Ki-Woong Yoon, Byung-Woo |
author_facet | Kim, Yerim Lee, Sang-Hwa Kang, Min Kyoung Kim, Tae Jung Jeong, Han-Yeong Lee, Eung-Joon Bae, Jeonghoon Jeon, Kipyoung Nam, Ki-Woong Yoon, Byung-Woo |
author_sort | Kim, Yerim |
collection | PubMed |
description | Background: There is growing interest in the use of new biomarkers such as glycated albumin (GA), but data are limited in acute ischemic stroke. We explored the impact of GA on short-term functional outcomes as measured using the modified Rankin Scale (mRS) at 3 months compared to glycated hemoglobin (HbA1c). Methods: A total of 1163 AIS patients from two hospitals between 2016 and 2019 were included. Patients were divided into two groups according to GA levels (GA < 16% versus GA ≥ 16%). Results: A total of 518 patients (44.5%) were included in the GA ≥ 16% group. After adjusting for multiple covariates, the higher GA group (GA ≥ 16%) had a 1.4-fold risk of having unfavorable mRS (95% CI 1.02–1.847). However, HbA1c was not significantly associated with 3-month mRS. In addition, GA ≥ 16% was independently associated with unfavorable short-term outcomes only in patients without diabetes. Conclusions: In light of these results, GA level might be a novel prognostic biomarker compared to HbA1c for short-term stroke outcome. Although the impact of GA is undervalued in the current stroke guidelines, GA monitoring should be considered in addition to HbA1c monitoring. |
format | Online Article Text |
id | pubmed-8000654 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-80006542021-03-28 Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke Kim, Yerim Lee, Sang-Hwa Kang, Min Kyoung Kim, Tae Jung Jeong, Han-Yeong Lee, Eung-Joon Bae, Jeonghoon Jeon, Kipyoung Nam, Ki-Woong Yoon, Byung-Woo Brain Sci Article Background: There is growing interest in the use of new biomarkers such as glycated albumin (GA), but data are limited in acute ischemic stroke. We explored the impact of GA on short-term functional outcomes as measured using the modified Rankin Scale (mRS) at 3 months compared to glycated hemoglobin (HbA1c). Methods: A total of 1163 AIS patients from two hospitals between 2016 and 2019 were included. Patients were divided into two groups according to GA levels (GA < 16% versus GA ≥ 16%). Results: A total of 518 patients (44.5%) were included in the GA ≥ 16% group. After adjusting for multiple covariates, the higher GA group (GA ≥ 16%) had a 1.4-fold risk of having unfavorable mRS (95% CI 1.02–1.847). However, HbA1c was not significantly associated with 3-month mRS. In addition, GA ≥ 16% was independently associated with unfavorable short-term outcomes only in patients without diabetes. Conclusions: In light of these results, GA level might be a novel prognostic biomarker compared to HbA1c for short-term stroke outcome. Although the impact of GA is undervalued in the current stroke guidelines, GA monitoring should be considered in addition to HbA1c monitoring. MDPI 2021-03-06 /pmc/articles/PMC8000654/ /pubmed/33800924 http://dx.doi.org/10.3390/brainsci11030337 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) ). |
spellingShingle | Article Kim, Yerim Lee, Sang-Hwa Kang, Min Kyoung Kim, Tae Jung Jeong, Han-Yeong Lee, Eung-Joon Bae, Jeonghoon Jeon, Kipyoung Nam, Ki-Woong Yoon, Byung-Woo Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke |
title | Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke |
title_full | Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke |
title_fullStr | Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke |
title_full_unstemmed | Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke |
title_short | Glycated Albumin, a Novel Biomarker for Short-Term Functional Outcomes in Acute Ischemic Stroke |
title_sort | glycated albumin, a novel biomarker for short-term functional outcomes in acute ischemic stroke |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8000654/ https://www.ncbi.nlm.nih.gov/pubmed/33800924 http://dx.doi.org/10.3390/brainsci11030337 |
work_keys_str_mv | AT kimyerim glycatedalbuminanovelbiomarkerforshorttermfunctionaloutcomesinacuteischemicstroke AT leesanghwa glycatedalbuminanovelbiomarkerforshorttermfunctionaloutcomesinacuteischemicstroke AT kangminkyoung glycatedalbuminanovelbiomarkerforshorttermfunctionaloutcomesinacuteischemicstroke AT kimtaejung glycatedalbuminanovelbiomarkerforshorttermfunctionaloutcomesinacuteischemicstroke AT jeonghanyeong glycatedalbuminanovelbiomarkerforshorttermfunctionaloutcomesinacuteischemicstroke AT leeeungjoon glycatedalbuminanovelbiomarkerforshorttermfunctionaloutcomesinacuteischemicstroke AT baejeonghoon glycatedalbuminanovelbiomarkerforshorttermfunctionaloutcomesinacuteischemicstroke AT jeonkipyoung glycatedalbuminanovelbiomarkerforshorttermfunctionaloutcomesinacuteischemicstroke AT namkiwoong glycatedalbuminanovelbiomarkerforshorttermfunctionaloutcomesinacuteischemicstroke AT yoonbyungwoo glycatedalbuminanovelbiomarkerforshorttermfunctionaloutcomesinacuteischemicstroke |